Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | GLI1 | P08151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40093 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL248746 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Bromide SCHEMBL27517782 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL596114 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL661790 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL661789 | 0.98 | NOS2 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL2804278 | 0.95 | SCN9A (0.39) | NOS2NOS3NOS1DPP4DPP8 | |
| Oxalic Acid SCHEMBL9353931 | 0.95 | DPP4 (0.40) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL7384758 | 0.95 | SCN9A (0.37) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL7384762 | 0.95 | SCN9A (0.37) | NOS2NOS3NOS1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026042018-A1 | 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES | PFIZER INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4688777-A1 | NOVEL PD-L1 INHIBITORS | Affirma Biotech S. L. (ES) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025224599-A1 | PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2001056987-A1 | TOSYLPROLINE ANALOGS AS THYMIDYLATE SYNTHASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6262089-B1 | USING THESE COMPOUNDS TO TREAT DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, MATURITY ONSET DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE. | HOFFMAN-LA ROCHE INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6143776-A | Tosylproline analogs as thymidylate synthase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6103910-A | FOR TREATMENT OF DISEASES ASSOCIATED WITH AMYLOIDOSIS, SUCH AS ALZHEIMER'S DISEASE, DIABETES MELLITUS, FAMILIAL AMYLOID POLYNEUROPATHY, SCRAPIE, AND KREUZFELD-JACOB DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-08-15 | — | — | US | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0915088-A1 | D-Proline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | NOS2 1764/4885NOS3 2165/4885NOS1 1158/4885 |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | NOS2 3956/4885NOS3 2513/4885NOS1 2957/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | NOS2 1764/4885NOS3 2165/4885NOS1 1158/4885 |
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | IL2, CD47, EPCAM | NOS2 920/4885NOS3 2604/4885NOS1 2653/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | NOS2 1764/4885NOS3 2165/4885NOS1 1158/4885 |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | NOS2 2113/4885NOS3 1544/4885NOS1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.